PL378294A1 - Pochodne izochinolinowe i sposoby ich stosowania - Google Patents
Pochodne izochinolinowe i sposoby ich stosowaniaInfo
- Publication number
- PL378294A1 PL378294A1 PL378294A PL37829404A PL378294A1 PL 378294 A1 PL378294 A1 PL 378294A1 PL 378294 A PL378294 A PL 378294A PL 37829404 A PL37829404 A PL 37829404A PL 378294 A1 PL378294 A1 PL 378294A1
- Authority
- PL
- Poland
- Prior art keywords
- methods
- isoquinoline derivatives
- isoquinoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/376,746 US6956035B2 (en) | 2001-08-31 | 2003-02-28 | Isoquinoline derivatives and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL378294A1 true PL378294A1 (pl) | 2006-03-20 |
Family
ID=32961227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL378294A PL378294A1 (pl) | 2003-02-28 | 2004-02-26 | Pochodne izochinolinowe i sposoby ich stosowania |
Country Status (11)
Country | Link |
---|---|
US (3) | US6956035B2 (pl) |
EP (1) | EP1603568A4 (pl) |
JP (1) | JP2006520817A (pl) |
KR (1) | KR20050118168A (pl) |
CN (2) | CN101270087A (pl) |
AU (1) | AU2004218023A1 (pl) |
BR (1) | BRPI0407922A (pl) |
CA (1) | CA2517358A1 (pl) |
PL (1) | PL378294A1 (pl) |
RU (2) | RU2005130159A (pl) |
WO (1) | WO2004078712A2 (pl) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956035B2 (en) * | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
US20030096833A1 (en) * | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
CA2517260A1 (en) * | 2003-02-28 | 2005-02-03 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
US10425538B2 (en) * | 2003-10-06 | 2019-09-24 | Yellowpages.Com Llc | Methods and apparatuses for advertisements on mobile devices for communication connections |
KR20060125909A (ko) * | 2004-02-26 | 2006-12-06 | 이노텍 파마슈티컬스 코포레이션 | 이소퀴놀린 유도체 및 이의 사용 방법 |
BRPI0508052A (pt) * | 2004-02-26 | 2007-07-17 | Inotek Pharmaceuticals Corp | derivados de lactamo tetracìclico e seus usos |
EP1784186A4 (en) * | 2004-06-16 | 2008-05-14 | Inotek Pharmaceuticals Corp | METHODS OF TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE |
AU2006219022A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Isoqunoline Compounds and methods of use thereof |
WO2006093667A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic amino and carboxamido compounds and methods of use thereof |
US20060287311A1 (en) * | 2005-02-25 | 2006-12-21 | Inotek Pharmaceuticals Corporation | Tetracyclic Sulfonamide Compounds and methods of use thereof |
WO2007008926A1 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
WO2007025009A2 (en) * | 2005-08-24 | 2007-03-01 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
RU2009135818A (ru) * | 2007-02-28 | 2011-04-10 | Инотек Фармасьютикалз Корпорейшн (Us) | Инденоизохинолиноновые аналоги и способы их применения |
US8455514B2 (en) * | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
EP3828172A1 (en) | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
CA2798697A1 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
US9173395B2 (en) | 2011-07-04 | 2015-11-03 | Bayer Intellectual Property Gmbh | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants |
CA2857344C (en) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
JP5929229B2 (ja) * | 2012-01-24 | 2016-06-01 | 東洋紡株式会社 | アルカリホスファターゼ |
JP6505013B2 (ja) | 2012-08-28 | 2019-04-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 |
AU2014222641B2 (en) | 2013-02-28 | 2018-03-15 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
CN105263494A (zh) | 2013-03-15 | 2016-01-20 | 爱瑞制药公司 | 联合治疗 |
JP6419155B2 (ja) | 2013-04-03 | 2018-11-07 | ヤンセン・サイエンシズ・アイルランド・ユーシー | N−フェニル−カルボキサミド誘導体およびb型肝炎を治療するための医薬品としてのその使用 |
US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
LT3024819T (lt) | 2013-07-25 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui |
WO2015059212A1 (en) | 2013-10-23 | 2015-04-30 | Janssen R&D Ireland | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
MX2016009449A (es) | 2014-02-05 | 2016-10-13 | Novira Therapeutics Inc | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). |
EP3102572B1 (en) | 2014-02-06 | 2018-10-24 | Janssen Sciences Ireland UC | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
WO2017086941A1 (en) | 2015-11-17 | 2017-05-26 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
JP6907319B2 (ja) | 2016-08-31 | 2021-07-21 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼科用組成物 |
KR102009756B1 (ko) | 2017-01-06 | 2019-08-12 | 고려대학교 세종산학협력단 | 신규한 퀴놀리논 유도체 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물 |
JP2020515583A (ja) | 2017-03-31 | 2020-05-28 | アエリエ ファーマシューティカルズ インコーポレイテッド | アリールシクロプロピル−アミノ−イソキノリニルアミド化合物 |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2020056345A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
CN113454077A (zh) | 2019-02-22 | 2021-09-28 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
MX2021013594A (es) | 2019-05-06 | 2021-12-10 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US96833A (en) * | 1869-11-16 | Improvement in barrel-filling- apparatus with whistling indicators | ||
US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
IT1054655B (it) * | 1975-08-27 | 1981-11-30 | Lepetit Spa | Derivati condensati del l isochinolina |
US4263304A (en) * | 1978-06-05 | 1981-04-21 | Sumitomo Chemical Company, Limited | 7 H-indolo[2,3-c]isoquinolines |
GB2025932B (en) | 1978-06-13 | 1982-10-27 | Sumitomo Chemical Co | Indoloisoquinolines and processes for producing them |
JPS57172923A (en) | 1981-04-17 | 1982-10-25 | Toray Ind Inc | Production of polybutylene terephthalate polymer fine particle |
GB8828806D0 (en) * | 1988-12-09 | 1989-01-18 | Beecham Group Plc | Novel compounds |
US5260316A (en) * | 1991-07-30 | 1993-11-09 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
US5597831A (en) * | 1991-08-29 | 1997-01-28 | Vufb A.S | 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents |
CZ281473B6 (cs) | 1991-08-29 | 1996-10-16 | Vúfb, A.S. | Deriváty 6-/X-(2-hydroxyethyl)aminoalkyl/-5,11 -dioxo-5,6-dihydro-11H-indeno/1,2-c/-isochinolinu a způsob jejich výroby |
US5262564A (en) * | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
TW440562B (en) * | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
WO1999008680A1 (en) | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
US6250301B1 (en) | 1997-08-28 | 2001-06-26 | Hortal Harm B.V. | Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix |
WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US6346536B1 (en) * | 1997-09-03 | 2002-02-12 | Guilford Pharmaceuticals Inc. | Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
EP1077946A1 (en) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
JP2002515488A (ja) | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | カルボキサミド化合物、組成物、及びparp活性の抑制方法 |
AU765135B2 (en) | 1998-10-14 | 2003-09-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Novel indenoisoquinolines as antineoplastic agents |
TR200200972T2 (tr) | 1998-11-03 | 2002-07-22 | Basf Aktiengesellschaft | İkameli 2-fenilbenzimidazoller, üretimleri ve kullanımları |
US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
MXPA01007001A (es) | 1999-01-11 | 2002-07-30 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas. |
US6346535B1 (en) * | 1999-01-29 | 2002-02-12 | American Cyanamid Company | Fungicidal mixtures |
US6465448B1 (en) | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US6723733B2 (en) | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
GB0017508D0 (en) | 2000-07-17 | 2000-08-30 | Novartis Ag | Antimicrobials |
US6790199B1 (en) | 2000-09-28 | 2004-09-14 | North American Medical Products, Inc. | Needle protective assembly for multi-draw needle |
ITMI20002358A1 (it) * | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
US20030096833A1 (en) * | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
JP2003267888A (ja) | 2002-03-15 | 2003-09-25 | Seishi Yoneda | 心停止液 |
WO2004014862A1 (en) | 2002-08-09 | 2004-02-19 | Rutgers, The State University | Nitro and amino substituted heterocycles as topoisomerase i targeting agents |
CA2517260A1 (en) * | 2003-02-28 | 2005-02-03 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
JP5545690B2 (ja) | 2003-12-01 | 2014-07-09 | クドス ファーマシューティカルズ リミテッド | 癌治療のためのdna損傷修復阻害剤 |
KR20060125909A (ko) * | 2004-02-26 | 2006-12-06 | 이노텍 파마슈티컬스 코포레이션 | 이소퀴놀린 유도체 및 이의 사용 방법 |
-
2003
- 2003-02-28 US US10/376,746 patent/US6956035B2/en not_active Expired - Fee Related
-
2004
- 2004-02-26 JP JP2006508867A patent/JP2006520817A/ja active Pending
- 2004-02-26 EP EP04715130A patent/EP1603568A4/en not_active Withdrawn
- 2004-02-26 RU RU2005130159/04A patent/RU2005130159A/ru not_active Application Discontinuation
- 2004-02-26 AU AU2004218023A patent/AU2004218023A1/en not_active Abandoned
- 2004-02-26 WO PCT/US2004/005849 patent/WO2004078712A2/en active Application Filing
- 2004-02-26 PL PL378294A patent/PL378294A1/pl unknown
- 2004-02-26 CA CA002517358A patent/CA2517358A1/en not_active Abandoned
- 2004-02-26 CN CNA2007101991849A patent/CN101270087A/zh active Pending
- 2004-02-26 CN CNB2004800114238A patent/CN100400515C/zh not_active Expired - Fee Related
- 2004-02-26 BR BRPI0407922-1A patent/BRPI0407922A/pt not_active IP Right Cessation
- 2004-02-26 KR KR1020057016094A patent/KR20050118168A/ko not_active Application Discontinuation
- 2004-10-12 US US10/963,293 patent/US7268143B2/en not_active Expired - Fee Related
-
2005
- 2005-07-08 US US11/177,161 patent/US7393955B2/en not_active Expired - Fee Related
-
2009
- 2009-11-27 RU RU2009144059/04A patent/RU2009144059A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20050282848A1 (en) | 2005-12-22 |
CN1780625A (zh) | 2006-05-31 |
CA2517358A1 (en) | 2004-09-16 |
WO2004078712A2 (en) | 2004-09-16 |
US6956035B2 (en) | 2005-10-18 |
KR20050118168A (ko) | 2005-12-15 |
EP1603568A4 (en) | 2009-02-25 |
CN100400515C (zh) | 2008-07-09 |
RU2009144059A (ru) | 2011-06-10 |
RU2005130159A (ru) | 2006-03-27 |
WO2004078712A3 (en) | 2005-02-24 |
CN101270087A (zh) | 2008-09-24 |
AU2004218023A1 (en) | 2004-09-16 |
EP1603568A2 (en) | 2005-12-14 |
US7268143B2 (en) | 2007-09-11 |
BRPI0407922A (pt) | 2006-03-01 |
US20050049270A1 (en) | 2005-03-03 |
US20040039009A1 (en) | 2004-02-26 |
JP2006520817A (ja) | 2006-09-14 |
US7393955B2 (en) | 2008-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL378294A1 (pl) | Pochodne izochinolinowe i sposoby ich stosowania | |
IL177650A0 (en) | Isoquinoline derivatives and methods of use thereof | |
EP1465615A4 (en) | TRICYCLIC BISENONE DERIVATIVES AND METHODS OF USE | |
EP1603567A4 (en) | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF | |
IL172986A0 (en) | Hairpin -labeled probes and methods of use | |
ZA200600387B (en) | Hydrolytically-resistant bornon-containing therapeutics and methods of use | |
AU2003217870A8 (en) | Pini-modulating compounds and methods of use thereof | |
HK1079789A1 (zh) | 血管靜態毒性試劑及其使用方法 | |
AU2003213673A8 (en) | Pin1-modulating compounds and methods of use thereof | |
PL377861A1 (pl) | Podstawione pochodne aminowe oraz sposoby wykorzystania | |
AU2003284808A8 (en) | The derivatives of pyridone and the use of them | |
HK1116800A1 (en) | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | |
ZA200500680B (en) | Quinoline derivatives and their use as mycrobacterial inhibitors | |
AU2003303128A8 (en) | Inhibitors and methods of use thereof | |
IL173967A0 (en) | Lipid system and methods of use | |
IL213843A0 (en) | 4-aminotetracyclines and methods of use thereof | |
EP1843768A4 (en) | SUBSTITUTED MORPHINANES AND METHODS OF USE | |
EP1639086A4 (en) | RNA INTERFERASES AND METHODS OF USE | |
PL377413A1 (pl) | Pochodne piryd-2-onu i sposoby ich zastosowania | |
ZA200601293B (en) | Proteasome inhibitors and methods of using the same | |
EP1625111A4 (en) | THYRONAMINE DERIVATIVES AND ANALOGUES AND METHODS OF USE THEREOF | |
EP1476150A4 (en) | CARBOXY FULLERES AND USE METHOD THEREFOR | |
EP1633749A4 (en) | DEAZAFLAVIN COMPOUNDS AND METHODS OF USE | |
AU2003297612A8 (en) | 2-substituted-3-propenamide derivatives and methods of using the same | |
EP1625141A4 (en) | GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |